March 12, 2010
As the incidence of diabetes and hypertension continues to grow worldwide – and increasing numbers of patients progressing to kidney disease and kidney failure place a financial strain on public health systems – the need for early patient education about kidney disease and treatment options, including home-based treatments, has become critical. More than 240 million people have diabetes and this figure is projected to rise to 380 million by 20251. In the United States alone, 17.9 million have been diagnosed with diabetes resulting in medical and indirect costs (e.g…
Go to Source… Continue reading
March 12, 2010
Terry Burnside, general manager and senior vice president responsible for Medicine Shoppe and Medicap Pharmacy operations, today issued the following statement in response to a lawsuit filed in U.S. District Court in the Southern District of Ohio by seven Medicine Shoppe and Medicap franchisees, purporting to represent a class: Medicine Shoppe is dedicated to serving the needs of retail pharmacies and to helping them succeed. This has been true since 1970 when we began, and it is a value we hold sacred today…
Go to Source… Continue reading
March 12, 2010
Boston Scientific Corporation (NYSE: BSX) announced the schedule of the Company’s major events and news announcements at the 59th Annual Scientific Session of the American College of Cardiology/i2 Summit, March 13-16 in Atlanta. “We look forward to announcing 12-month results from the PERSEUS clinical program, which will provide important data on our third-generation drug-eluting stent, the TAXUS® Element™ Paclitaxel-Eluting Stent,” said Keith Dawkins, M.D., Senior Vice President and Chief Medical Officer for Boston Scientific…
Go to Source… Continue reading
March 12, 2010
Cancer patients in Kent will gain access to advanced radiotherapy treatments with the decision by the Kent Oncology Centre to acquire two fully-equipped treatment machines from Varian Medical Systems (NYSE: VAR). The machines, due to be delivered to oncology departments in Maidstone and Canterbury in the spring, will mean these departments are among the first in the country to offer fast and efficient RapidArc® radiotherapy treatments…
Go to Source… Continue reading
March 12, 2010
Clinicians at the Rinecker Proton Therapy Center (RPTC) in Munich have treated their 100th patient using advanced proton therapy systems supplied by Varian Medical Systems (NYSE: VAR). The landmark treatment comes just three months after a second treatment gantry was commissioned at the center, which offers advanced pencil-beam proton scanning to cancer patients. These patients, requiring treatment for a wide range of cancers, have come from across Germany and 19 other countries, including Canada, Argentina, the UK and Switzerland…
Go to Source… Continue reading
March 12, 2010
On March 10-11, 2010, the Joint Advisory Committees of the U.S. Food and Drug Administration (FDA) — including the Pulmonary-Allergy Drugs and the Drug Safety and Risk Management Advisory Committees — discussed the design of post-marketing safety studies for long-acting beta-agonist (LABA)-containing products in the U.S., including SYMBICORT® (budesonide/formoterol fumarate dihydrate)…
Go to Source… Continue reading
March 12, 2010
With obesity in America reaching alarming levels — across our adult and youth populations — results from a clinical trial unveiled by BodyMedia confirm that participants who used BodyMedia’s wearable body-monitoring technology either in conjunction with a group weight loss program or as part of their own self-directed program lost up to three times more weight than individuals who attempted to battle the bulge solo. BodyMedia Inc…
Go to Source… Continue reading
March 12, 2010
UCB announced that the antiepileptic drug (AED) Vimpat® (lacosamide) (C-V) demonstrated significantly fewer partial-onset seizures versus placebo in adults living with epilepsy, according to a Phase III clinical study published online in Epilepsia. This study was one of three that supported the approval of Vimpat by the U.S. Food and Drug Administration (FDA) in 2008 for use as an add-on therapy for the treatment of partial-onset seizures in people with epilepsy who are 17 years and older. Previous studies have demonstrated that Vimpat has a novel mechanism of action…
Go to Source… Continue reading
